Cloudbreak Therapeutics

Cloudbreak Therapeutics is a clinical-stage biotechnology company pioneering the future of eye care through efficient drug repurposing and fast-tracked clinical advancements. Established in 2015, the company focuses on ocular drug development, employing a capital-efficient business model based on VIC + 505b(2). This approach involves repurposing approved systemic drugs for ocular delivery to effectively treat various eye diseases. The company’s strategy enables the rapid advancement of drug candidates, moving swiftly through proof-of-concept (POC) Phase II clinical trials. Subsequently, they out-license global rights for Phase III clinical trials, product registration, and commercialization. Cloudbreak Therapeutics is fully engaged in the pharmaceutical development ecosystem, optimizing capital for drug development by partnering with contract research organizations (CRO) for non-clinical, CMC, and clinical development. In a significant milestone, Cloudbreak Therapeutics secured a substantial $130.00M Series C investment on January 1, 2022. The investment consortium included prominent firms such as EFung Capital, CDH Investments, CCB International, Dyee Capital, Grand Pharma, Industrial Securities Capital, CDF-Capital, Yuejun Investment, Yingke Capital, and ShenZhen GTJA Investment Group. This strategic investment underscores the confidence and support from leading investors in the company's innovative approach and its potential to revolutionize eye care. With a clear focus on biotechnology and healthcare industries, Cloudbreak Therapeutics stands poised to drive significant advancements in ocular drug development and positively impact the future of eye care.